Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
Meeting ReportOral - PhysicianPharm

Imaging non-coding microRNA upregulation in pressure overload heart failure using the complementary anti-miR-21 locked nucleic acid

James Thackeray, Eike Janssen, Aylina Glasenapp, Jan Fiedler, Thomas Thum, Frank Bengel and Tobias Ross
Journal of Nuclear Medicine May 2021, 62 (supplement 1) 138;
James Thackeray
1Department of Nuclear Medicine Hannover Medical School Hannover Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eike Janssen
1Department of Nuclear Medicine Hannover Medical School Hannover Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aylina Glasenapp
2Department of Experimental Radiology Hannover Medical School Hannover Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jan Fiedler
3Institute for Molecular and Translational Therapeutic Strategies Hannover Medical School Hannover Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Thum
3Institute for Molecular and Translational Therapeutic Strategies Hannover Medical School Hannover Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frank Bengel
1Department of Nuclear Medicine Hannover Medical School Hannover Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tobias Ross
1Department of Nuclear Medicine Hannover Medical School Hannover Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

138

Objectives: Non-coding ribonucleic acids (RNA) are upregulated in heart failure, during which they modulate ventricle remodeling. Selective inhibitors of microRNA-21 (miR-21) interfere with fibrotic signaling and improve cardiac function in small and large animal models. But the transient and non-tissue-specific upregulation of miR-21 may require precise timing for optimal therapeutic efficacy. We aimed to image cardiac miR-21 in vivo to characterize its temporal and spatial distribution in pressure overload heart failure.

Methods: The locked nucleic acid (LNA) miR-21 complementary 15mer strand (anti-miR-21) bearing a hexyl-disulfide moiety was used for coupling or labeling via maleimide-thiol-coupling. The subsequent derivative NODAGA-anti-miR-21 was utilized for labeling with gallium-68; the prosthetic group 18F-FPyME allowed labeling with fluorine-18 for positron emission tomography (PET). Tracer stability was assessed in human serum. C57Bl6 mice (n=14) underwent dynamic PET image acquisition to delineate kinetics and biodistribution of the labeled anti-miR-21-LNA constructs. An additional group of mice underwent transverse aortic constriction (TAC, n=6) to induce pressure overload heart failure, or sham surgery (n=4). Serial imaging was conducted at 7d and 21d after injury. Mice were administered 68Ga-anti-miR-21-LNA (11.7±1.5MBq) and a static image was acquired over 30-60min after injection. Tracer distribution was validated by ex vivo autoradiography and histopathology in adjacent ventricle sections.

Results: Both 68Ga- and 18F-anti-miR-21-LNA exhibited high stability in human serum over 120min (85-90% authentic compound). In healthy mice, 68Ga-anti-miR-21-LNA displayed rapid clearance from blood and accumulation in the liver. Low signal was observed in the myocardium, as confirmed by ex vivo biodistribution (% injected dose (ID)/g; 2.1±0.6). Pretreatment with unlabeled anti-miR-21-LNA (20mg/kg ip) did not affect tracer accumulation in target organs. Thin layer chromatography revealed predominantly unchanged tracer in blood and urine at 60min after injection and some hydrophilic metabolites. In heart failure mice, in vivo imaging did not reveal differences in the cardiac tracer accumulation between TAC and sham at 7d (%ID/g: 2.7±1.0 vs 2.7±0.7, p=0.982) or 21d (2.6±1.4 vs 3.3±2.0, p=0.581), due to significant spillover of liver activity (12-17%ID/g). However, ex vivo autoradiography revealed diffuse global enrichment of 68Ga-anti-miR-21-LNA throughout the left ventricle at 21d after TAC compared to sham (~3-fold). Masson trichrome histology identified interstitial collagen deposition throughout the left ventricle, consistent with pressure overload-induced remodeling. Quantitative PCR confirmed upregulation of miR21 in TAC hearts at 7d compared to sham (1.21±0.48 vs 0.52±0.08, p=0.026) at a similar magnitude to the autoradiography signal increase. Initial images from healthy mice with 18F-anti-miR-21-LNA displayed lower liver spillover to the myocardium region, which may facilitate isolation of the myocardial signal in heart failure. Conclusions: Radiolabeled anti-miR-21-LNA delineated increased miR-21 expression in failing hearts. High hepatic signal is consistent with the well known accumulation of the LNA in this organ, but may complicate quantitative interpretation of in vivo cardiac images. Accordingly, strategies to suppress liver uptake may enable clearer visualization of non-coding RNA upregulation in heart failure and refine therapeutic strategies.

Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 62, Issue supplement 1
May 1, 2021
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Imaging non-coding microRNA upregulation in pressure overload heart failure using the complementary anti-miR-21 locked nucleic acid
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Imaging non-coding microRNA upregulation in pressure overload heart failure using the complementary anti-miR-21 locked nucleic acid
James Thackeray, Eike Janssen, Aylina Glasenapp, Jan Fiedler, Thomas Thum, Frank Bengel, Tobias Ross
Journal of Nuclear Medicine May 2021, 62 (supplement 1) 138;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Imaging non-coding microRNA upregulation in pressure overload heart failure using the complementary anti-miR-21 locked nucleic acid
James Thackeray, Eike Janssen, Aylina Glasenapp, Jan Fiedler, Thomas Thum, Frank Bengel, Tobias Ross
Journal of Nuclear Medicine May 2021, 62 (supplement 1) 138;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Oral - PhysicianPharm

  • Blood based genomic assessment of the clinical efficacy and toxicity of peptide receptor radionuclide therapy (PRRT)
  • S1R PET/MRI of patients with chronic knee pain reveals potential pain generators not otherwise identified with standard care: Early experience.
  • 68Ga-Pentixafor PET/CT in the evaluation of post-treatment response for Waldenström Macroglobulinemia/ Lymphoplasmacytic Lymphoma
Show more Oral - PhysicianPharm

Cardiovascular Molecular Imaging

  • Targeted NPR-C PET/MR imaging of carotid atherosclerosis in humans: correlation with ex vivo plaque immunohistochemistry (IHC) and patient outcomes
  • 99mTc-PYP SPECT/CT cardiac transthyretin amyloidosis studies: cardiac-to-blood pool ratios versus visual interpretation
Show more Cardiovascular Molecular Imaging

Similar Articles

SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire